---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-079143"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2022-07-12T23:59:59+00:00"
generated_at: "2026-06-24T16:52:37.084082+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics expands Genentech immuno-oncology collaboration; receives $10M option exercise payment

## Summary
- Genentech exercised second option to add a new program to the existing 2020 collaboration, triggering a $10M payment to Bicycle.
- First expansion option under the same agreement was exercised in October 2021, also for $10M.
- Collaboration covers discovery and preclinical development of novel Bicycle-based immunotherapies against multiple targets.
- Bicycle's wholly owned oncology pipeline, including its immuno-oncology candidates, is not part of the collaboration.

## SEC filing metadata
- accession: 0001104659-22-079143
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2022-07-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465922079143/0001104659-22-079143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465922079143/tm2220703d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-079143
- JSON: https://secwatch.observer/filing/0001104659-22-079143.json
- Plain text: https://secwatch.observer/filing/0001104659-22-079143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.